CN104800664A - Medicine for treating amblyopia disease - Google Patents
Medicine for treating amblyopia disease Download PDFInfo
- Publication number
- CN104800664A CN104800664A CN201510262259.8A CN201510262259A CN104800664A CN 104800664 A CN104800664 A CN 104800664A CN 201510262259 A CN201510262259 A CN 201510262259A CN 104800664 A CN104800664 A CN 104800664A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- parts
- medicine
- weight
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses medicine for treating amblyopia diseases. The medicine comprises the following components in parts by weight: 2 to 5 parts of cassia seeds, 3 to 6 parts of dendrobium nobile, 2 to 5 parts of angelica sinensis, 2 to 5 parts of radix paeoniae alba, 2.5 to 4 parts of seed of glabrousleaf pittosporum, 1 to 3 parts of radix astragali, 1 to 3 parts of semen cuscutae, 0.5 to 2 parts of golden cypress, 0.5 to 2 parts of Chinese thorowax root, 1.5 to 3 parts of lophatherum gracile, 0.3 to 1.2 parts of pilocarpine, 0.5 to 1.5 parts of anisodine, 0.1 to 0.3 part of diluting agent and 0.1 to 0.3 part of absorbing agent. On the basis of the treatment rule for tonifying the liver and kidney, strengthening the spleen and nourishing the blood, the problems that the existing amblyopia curative effect is poor and the vision deterioration ocurres after the treatment is stopped can be overcome.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, be specifically related to a kind of medicine for the treatment of eye disease of amblyopia.
Background technology
After raw, (visual development critical period) stravismus, anisometropia or the abnormal vision such as ametropia, form deprivation experience cause amblyopia in early days.Since half a century, about the concept of amblyopia, Chinese scholars generally adopts Bangerter to schedule, namely " eye itself is without organic change; or have organic change and ametropia, but the visual deterioration incompatible with its pathological changes, ametropia also can not be corrected; distant place vision, 0.8 (0.9) following person, is referred to as amblyopia.”。
The therapeutic effect of amblyopia is close relevant to the age, also closely related with amblyopia degree, type and watching attentively property, early discovery and adhere to Comprehensive Treatment be treatment amblyopia key.It is generally accepted as critical period or sensitive period refer to children's from birth to 6 years old in the world, average out to 8.5 years old at the latest, sickness rate is 3-4%, and 0-7 year be the optimal treatment phase, 12 years old later therapeutic effect extreme difference.At present, the Therapeutic Method of amblyopia is based on physiotherapy, and wherein traditional " occlusion therapy " although gone through more than 200 year adopt, but still is considered to main and the most effective Therapeutic Method at present.
Summary of the invention
The object of the invention is to for deficiency of the prior art, a kind of medicine for the treatment of eye disease of amblyopia is provided, solve the problem that amblyopia in prior art stops the vision rollback after treating.
For solving the problems of the technologies described above, the technical solution used in the present invention is: a kind of medicine for the treatment of eye disease of amblyopia, this medicine comprises the component of following weight portion: Semen Cassiae 2-5 weight portion, Herba Dendrobii 3-6 weight portion, Radix Angelicae Sinensis 2-5 weight portion, Radix Paeoniae Alba 2-5 weight portion, wide Semen Pittospori Glabrati 2.5-4 weight portion, Huang Shi 1-3 weight portion, Semen Cuscutae 1-3 weight portion, Cortex Phellodendri 0.5-2 weight portion, Radix Bupleuri 0.5-2 weight portion, Herba Lophatheri 1.5-3 weight portion, pilocarpine 0.3-1.2 weight portion, Anisodine 0.5-1.5 weight portion, diluent 0.1-0.3 weight portion, absorbent 0.1-0.3 weight portion,
Described diluent is: arginine 0.5-1 weight portion, glutamic acid 0.5-1 weight portion, aspartic acid 0.2-0.8 weight portion, tartaric acid 0.2-0.8 weight portion;
Described absorbent is: rhamnolipid 0.2-0.5 weight portion, Borneolum Syntheticum 0.6-1 weight portion, Fluoritum 0.6-1 weight portion, Carapax Eretmochelydis 0.6-1 weight portion.
Further, described medicine comprises the component of following weight portion: Semen Cassiae 3-4 weight portion, Herba Dendrobii 3.5-4.5 weight portion, Radix Angelicae Sinensis 3-4 weight portion, Radix Paeoniae Alba 3-3.6 weight portion, wide Semen Pittospori Glabrati 3-3.6 weight portion, Huang Shi 1.5-2.5 weight portion, Semen Cuscutae 1.5-2.5 weight portion, Cortex Phellodendri 0.8-1.5 weight portion, Radix Bupleuri 1-1.5 weight portion, Herba Lophatheri 2-2.5 weight portion, pilocarpine 0.5-1 weight portion, Anisodine 0.8-1.3 weight portion, diluent 0.12-0.2 weight portion, absorbent 0.12-0.2 weight portion, flocculating agent 0.12-0.2 weight portion.
Further, described medicine comprises the component of following weight portion: Semen Cassiae 3.2 weight portion, Herba Dendrobii 3.7 weight portion, Radix Angelicae Sinensis 3.6 weight portion, the Radix Paeoniae Alba 3.3 weight portion, wide Semen Pittospori Glabrati 3.2 weight portion, Huang Shi 2.2 weight portion, Semen Cuscutae 2.3 weight portion, Cortex Phellodendri 1.3 weight portion, Radix Bupleuri 1.2 weight portion, Herba Lophatheri 2.4 weight portion, pilocarpine 0.8 weight portion, Anisodine 1.2 weight portion, diluent 0.15 weight portion, absorbent 0.15 weight portion, flocculating agent 0.15 weight portion.
Another 0.07 hectare of the present invention is to provide a kind of method preparing described medicine, comprises the following steps:
(1) Semen Cassiae, Herba Dendrobii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, wide Semen Pittospori Glabrati, Huang Shi, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, Herba Lophatheri is taken by weight, clean, pulverize, add raw material gross weight 6-10 water doubly, once decoct at 90-100 DEG C, decoct 2-4 hour;
(2) raw material after decoction is crossed 160 mesh sieves, obtain first-time filtrate, for subsequent use, add its weight 4-6 water doubly in residue, at 90-100 DEG C, carry out secondary decoction, decoct 2-4 hour;
(3) raw material after decoction is crossed 320 mesh sieves, obtain secondary filtrate, for subsequent use, add its weight 2-3 water doubly in residue, at 90-100 DEG C, carry out three times decoct, decoct 2-4 hour;
(4) raw material after decoction is crossed 320 mesh sieves, obtain three filtrates, merge the filtrate decocted for three times, add the alcoholic solution mix homogeneously of 30-45 part 75-80%, at 0.9 normal atmosphere, 90-100 DEG C, be then concentrated into the density 1.2-1.5 relative to water;
(5) by the solution left standstill 20-24h after concentrated, supernatant is got, and concentrating under reduced pressure, reclaim ethanol, the medicine of the eye disease of amblyopia that namely obtains medical treatment.
Further, described medicine can be made into pill, tablet or granular preparation.
Semen Cassiae: bitter but sweet flavor, cool in nature, there is the effect of liver heat removing, improving eyesight, wind heat acute conjunctivitis, optic atrohic blindness, nyctalopia etc. can be controlled and take a disease (compiling " Chinese medicine voluminous dictionary " P949 see the new medical college in Jiangsu);
Herba Dendrobii (Dendrobium nobile or Dendrobium officinale), the micro-one-tenth of slightly sweet flavor, cold in nature, energy clearing away heat and nourishing YIN, can control the moon and hinder order dark (see " Chinese medicine voluminous dictionary " P586).
Wide Semen Pittospori Glabrati: i.e. Semen Pittospori Glabrati is the seed of Pittosporaceae plant Pittosporum glabratum Lindl. (Pittosporum glabratum), bitter and puckery flavor, and property is put down, energy heat clearing away, promoting the production of body fluid to quench thirst (see " Chinese medicine voluminous dictionary " P184).
Herba Lophatheri: (Lophatherum gracile), slightly sweet flavor, cold in nature, can clearing away heart-fire, heat clearing away and restlessness relieving (see " Chinese medicine voluminous dictionary " P2253).
Anisodine is that a kind of alkaloid is seen, has and alleviates the cholinolytic effect such as smooth muscle spasm, mydriasis, can regulate and maintain antiotasis, strengthens ocular blood flow amount.
Pilocarpine, causes myosis, and intraocular pressure declines, and has the effect of the spasm of accommodation, increases exocrine gland secretion.
Radix Angelicae Sinensis, the Radix Paeoniae Alba is ministerial drug.When being included into liver spleen heart channel, can tonifying liver blood and improving eyesight, mend and can manage it.The Radix Paeoniae Alba returns Liver and kidney warp, tonification liver blood, nourishing blood to suppress the hyperactive liver improving eyesight, the person that is specially adapted to deficiency of liver-blood.Share then sour and sweet drugs can transforme into YIN with Radix Angelicae Sinensis compatibility, liver is hidden to some extent, normal vision relying on sufficiency of liver-blood, makes the blood in liver reaches in order, plays the merit of nourishing blood for improving eyesight altogether.The Radix Astragali, Semen Cuscutae is adjuvant drug, and Radix Astragali benefiting QI for strengthening the superficies, arresting sweating take off admittedly, is QI invigorating good merchantable brand, can rises and can fall, and the yang aspect of yang also, can help the merit of Radix Angelicae Sinensis, Radix Paeoniae Alba nourishing blood to promote the production of body fluid.Semen Cuscutae the kidney invigorating and essence nourishing, nourishing the liver to improve visual acuity strengthening the spleen, not only can YANG invigorating but also can tonifying YIN, with Radix Rehmanniae Preparata with strengthening nourishing the liver to improve visual acuity effect with having.Cortex Phellodendri, Radix Bupleuri is for making medicine.The sedimentation of Cortex Phellodendri bitter cold, fire is made to go not impairment of YIN again, can prevent from causing hyperactivity of fire impairment of YIN with tonic for a long time, Radix Bupleuri removing nebula to improve visual acuity, elevate a turnable ladder yang-energy, can help its function of improving eyesight with Semen Cassiae, Herba Dendrobii, wide Semen Pittospori Glabrati and Herba Lophatheri compatibility, and another Radix Bupleuri can draw all medicines and to go directly eye, add the effect of Anisodine and pilocarpine, improve the drug effect of perfect square.
Beneficial effect of the present invention: medicine of the present invention is with liver and kidney tonifying, and spleen benefiting and replenishing qi and blood is Therapeutic Principle, overcomes the problem that existing amblyopia treating effect is not good, stop the vision rollback after treating.
Claims (5)
1. treat a medicine for eye disease of amblyopia, it is characterized in that: this medicine comprises the component of following weight portion: Semen Cassiae 2-5 weight portion, Herba Dendrobii 3-6 weight portion, Radix Angelicae Sinensis 2-5 weight portion, Radix Paeoniae Alba 2-5 weight portion, wide Semen Pittospori Glabrati 2.5-4 weight portion, Huang Shi 1-3 weight portion, Semen Cuscutae 1-3 weight portion, Cortex Phellodendri 0.5-2 weight portion, Radix Bupleuri 0.5-2 weight portion, Herba Lophatheri 1.5-3 weight portion, pilocarpine 0.3-1.2 weight portion, Anisodine 0.5-1.5 weight portion, diluent 0.1-0.3 weight portion, absorbent 0.1-0.3 weight portion;
Described diluent is: arginine 0.5-1 weight portion, glutamic acid 0.5-1 weight portion, aspartic acid 0.2-0.8 weight portion, tartaric acid 0.2-0.8 weight portion;
Described absorbent is: rhamnolipid 0.2-0.5 weight portion, Borneolum Syntheticum 0.6-1 weight portion, Fluoritum 0.6-1 weight portion, Carapax Eretmochelydis 0.6-1 weight portion.
2. a kind of medicine for the treatment of eye disease of amblyopia according to claim 1, it is characterized in that: this medicine comprises the component of following weight portion: Semen Cassiae 3-4 weight portion, Herba Dendrobii 3.5-4.5 weight portion, Radix Angelicae Sinensis 3-4 weight portion, Radix Paeoniae Alba 3-3.6 weight portion, wide Semen Pittospori Glabrati 3-3.6 weight portion, Huang Shi 1.5-2.5 weight portion, Semen Cuscutae 1.5-2.5 weight portion, Cortex Phellodendri 0.8-1.5 weight portion, Radix Bupleuri 1-1.5 weight portion, Herba Lophatheri 2-2.5 weight portion, pilocarpine 0.5-1 weight portion, Anisodine 0.8-1.3 weight portion, diluent 0.12-0.2 weight portion, absorbent 0.12-0.2 weight portion, flocculating agent 0.12-0.2 weight portion.
3. a kind of medicine for the treatment of eye disease of amblyopia according to claim 1, is characterized in that: this medicine comprises the component of following weight portion: Semen Cassiae 3.2 weight portion, Herba Dendrobii 3.7 weight portion, Radix Angelicae Sinensis 3.6 weight portion, the Radix Paeoniae Alba 3.3 weight portion, wide Semen Pittospori Glabrati 3.2 weight portion, Huang Shi 2.2 weight portion, Semen Cuscutae 2.3 weight portion, Cortex Phellodendri 1.3 weight portion, Radix Bupleuri 1.2 weight portion, Herba Lophatheri 2.4 weight portion, pilocarpine 0.8 weight portion, Anisodine 1.2 weight portion, diluent 0.15 weight portion, absorbent 0.15 weight portion, flocculating agent 0.15 weight portion.
4. prepare a method for medicine according to claim 1, it is characterized in that: comprise the following steps:
(1) Semen Cassiae, Herba Dendrobii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, wide Semen Pittospori Glabrati, Huang Shi, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, Herba Lophatheri is taken by weight, clean, pulverize, add raw material gross weight 6-10 water doubly, once decoct at 90-100 DEG C, decoct 2-4 hour;
(2) raw material after decoction is crossed 160 mesh sieves, obtain first-time filtrate, for subsequent use, add its weight 4-6 water doubly in residue, at 90-100 DEG C, carry out secondary decoction, decoct 2-4 hour;
(3) raw material after decoction is crossed 320 mesh sieves, obtain secondary filtrate, for subsequent use, add its weight 2-3 water doubly in residue, at 90-100 DEG C, carry out three times decoct, decoct 2-4 hour;
(4) raw material after decoction is crossed 320 mesh sieves, obtain three filtrates, merge the filtrate decocted for three times, add the alcoholic solution mix homogeneously of 30-45 part 75-80%, at 0.9 normal atmosphere, 90-100 DEG C, be then concentrated into the density 1.2-1.5 relative to water;
(5) by the solution left standstill 20-24h after concentrated, supernatant is got, and concentrating under reduced pressure, reclaim ethanol, the medicine of the eye disease of amblyopia that namely obtains medical treatment.
5. method according to claim 4, is characterized in that: described medicine can be made into pill, tablet or granular preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510262259.8A CN104800664A (en) | 2015-05-21 | 2015-05-21 | Medicine for treating amblyopia disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510262259.8A CN104800664A (en) | 2015-05-21 | 2015-05-21 | Medicine for treating amblyopia disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104800664A true CN104800664A (en) | 2015-07-29 |
Family
ID=53686143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510262259.8A Pending CN104800664A (en) | 2015-05-21 | 2015-05-21 | Medicine for treating amblyopia disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104800664A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10952063B2 (en) | 2019-04-09 | 2021-03-16 | Oracle International Corporation | Methods, systems, and computer readable media for dynamically learning and using foreign telecommunications network mobility management node information for security screening |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007091727A (en) * | 2005-08-31 | 2007-04-12 | Taisho Pharmaceut Co Ltd | Preventing or alleviating agent of asthenopia |
| CN103735727A (en) * | 2013-08-27 | 2014-04-23 | 山东施尔明眼科医院 | Traditional Chinese medicine for treating amblyopia and preparation method thereof |
-
2015
- 2015-05-21 CN CN201510262259.8A patent/CN104800664A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007091727A (en) * | 2005-08-31 | 2007-04-12 | Taisho Pharmaceut Co Ltd | Preventing or alleviating agent of asthenopia |
| CN103735727A (en) * | 2013-08-27 | 2014-04-23 | 山东施尔明眼科医院 | Traditional Chinese medicine for treating amblyopia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 崔庆霞: ""中西医结合治疗儿童弱视疗效观察"", 《河南中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10952063B2 (en) | 2019-04-09 | 2021-03-16 | Oracle International Corporation | Methods, systems, and computer readable media for dynamically learning and using foreign telecommunications network mobility management node information for security screening |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102188604A (en) | Medicament for treating myopia and presbyopia | |
| CN101954028A (en) | Medicinal pillow for preventing and treating myopic eyes | |
| CN104116900A (en) | Traditional Chinese medicine dressing for preventing and treating myopia and preparation method of traditional Chinese medicine dressing | |
| CN104056000A (en) | Traditional Chinese medicine for treating cataract | |
| CN102670993B (en) | Traditional Chinese medicine for treating cataract | |
| CN101647913B (en) | Traditional Chinese medicine preparation for treating senile cataract and viral keratitis | |
| CN103585363A (en) | Traditional Chinese medicine composition for treating senile cataract | |
| CN104800664A (en) | Medicine for treating amblyopia disease | |
| CN105125630A (en) | Eye drops and preparation method thereof | |
| CN102198227B (en) | Method for preparing Chinese medicine for treating yin-deficiency glaucoma | |
| CN103405609B (en) | Traditional Chinese medicine preparation for treating cataract | |
| CN107669807A (en) | It is a kind of to be used to treat Chinese medicine preparation of eye disease alleviation ophthalmic uncomfortable and preparation method thereof | |
| CN102755549B (en) | Drug for curing cataract and preparation method thereof | |
| CN105833232A (en) | Eyesight improving Xiaoyao traditional Chinese patent medicament and preparation method thereof | |
| CN101480459A (en) | Chinese medicinal composition for treating premature ejaculation and spermatorrhea caused by yin deficiency | |
| CN102366607B (en) | Traditional Chinese medicine lavipeditum agent for treating allergic rhinitis | |
| CN105796927B (en) | A kind of Chinese medicine composition for treating blepharospasm | |
| CN101313975B (en) | Anti-neurasthenic medicine liqueur | |
| CN104013831B (en) | A kind of medicine for treating cerebral blood supply insufficiency | |
| CN101987157B (en) | Medicine for treating nearsightedness and preparation method thereof | |
| CN103316159A (en) | Traditional Chinese medicine used for treating kidney deficiency, and preparation method thereof | |
| CN102579724B (en) | Chinese medicine composition for treating glaucoma | |
| CN102151326B (en) | Chinese medicine composition for curing hypertension and hyperlipaemia | |
| CN105125778A (en) | Sleep improvement and fatigue relief footbath powder and preparation and utilization method thereof | |
| CN105878663A (en) | Foot bath material recipe and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150729 |